RFID technology for non-invasive headache treatment

- Sep 28, 2018-

NeuroCore ElectroCore has introduced a non-invasive vagus nerve stimulator, gammaCore Sapphire, which uses RFID technology to set up device operations based on patient needs. This device can help adults with migraine or cluster headaches to treat acute pain at home without taking extra medication. The device is equipped with an RFID reader that reads the passive RFID tags built into the specified stored value card.

The device can use passive HF RFID technology to receive parameters for stimulation therapy and automatically set device parameters. When the patient places the device on the neck, it provides mild stimulation that stimulates the vagus nerve without the need for surgery.

RFID technology for non-invasive headache treatment

Patients can use GammaCore Sapphire to treat headaches at home without medication

Founded in 2005, ElectroCore provides neuromodulation therapy for patients with various diseases. The company said that the company conducted its first proof of concept in 2006 and found that nerve stimulation can treat a variety of diseases, such as asthma or epilepsy. In 2011, the company was approved to sell the headache treatment product in Europe. In 2014, ElectroCore underwent a controlled randomized clinical trial of cluster headache treatment, which was then approved by the FDA.

Cluster headaches are short-lived but very painful, while migraine is relatively less painful but more common. In the United States, approximately 40 million people suffer from migraine. More than half of patients with paroxysmal cluster headaches tested gammaCore Sapphire and found that headaches had disappeared significantly.

Most patients with recurrent headaches use over-the-counter medications to treat pain. According to Dan Duhart, core chief business officer at electroCore, GammaCore is a non-invasive, non-toxic alternative. The company sells its products through insurance companies and healthcare providers. Since the release in July 2018, approximately 8,000 patients have used the system. The FDA allows patients to use up to 6 times a day.

The gammaCore VNS treatment device is about the same size as a mobile phone and is read by a predetermined stored value card. The patient pays through the stored value card, which also prevents overuse of the device. As with drugs, patients must be prescribed according to their doctor's prescription, with monthly or weekly usage. The device offers a 30-day trial period. During the trial period, most patients responded well.

The company chose to partner with Asembia, a specialty pharmaceutical and therapeutic services company. Patients can recharge their stored value cards at the Asembia store. After recharging, Asembia enters data about the patient in the eetctroCore software and writes the number of recharges to the RFID card.

When using the gammaCore treatment device, the patient needs to use the stored value card to tap the RFID reader, the reader can read the tag ID number, and the tag ID number is also bound to the device's daily usage. After reading, the LED screen on the device will display the time and date, as well as the number of uses allowed on that day.

Mendez said the company considered a variety of technologies and chose RFID. Bar code technology is not durable enough to be waterproof and shockproof. Insurance companies prefer to use RFID stored-value card solutions rather than transmitting them over the Internet or applications.